BMI vs Body Fat: What Actually Measures Your Health

What BMI is, and what it was designed to do

Body Mass Index is weight divided by height squared (kg/m²). The standard adult categories are underweight <18.5, normal 18.5–24.9, overweight 25–29.9 and obesity ≥30, with class I 30–34.9, class II 35–39.9 and class III ≥40.

BMI is cheap, reproducible, needs nothing beyond a scale and a tape, and correlates with body fat across large groups, which is why every major guideline still uses it for screening. It was designed as a population statistic, and it is a blunt instrument for an individual. The error is not using BMI but treating a screening proxy as a diagnosis of health. Grade A 🟢

What BMI misses

1. It cannot separate fat from muscle. A muscular athlete can register an "obese" BMI with low body fat, because BMI reads mass, not composition.
2. It ignores fat distribution. Visceral fat around the organs is far more harmful than fat under the skin, and BMI cannot see the difference. → Fatty Liver / MASLD
3. It varies by ethnicity. Cardiometabolic risk rises at lower BMI in South Asian, East Asian and some other populations.
4. It misses "normal-weight obesity." A normal BMI can hide a high body-fat percentage with real metabolic risk.
5. It mislabels "sarcopenic obesity." High fat with low muscle, common in older adults, can hide at a normal BMI while carrying worse functional risk.

The remedy is to add context rather than discard BMI: a tape measure, and, where it will change management, body composition and metabolic labs. → How Obesity Should Be Evaluated

Waist circumference and waist-to-height ratio

The most valuable addition to BMI costs the price of a tape measure, capturing the central (visceral) fat BMI cannot see.

• Waist circumference. Commonly used thresholds for elevated risk are roughly >102 cm (40 in) in men and >88 cm (35 in) in women, with lower thresholds in South and East Asian populations. Measured at the top of the hip bone, breathing out normally.
• Waist-to-height ratio (WHtR). An increasingly favoured metric: a waist under half of height (ratio <0.5). It applies across most ethnicities and body sizes under one rule and independently predicts cardiometabolic risk, often better than BMI alone.
• Waist-to-hip ratio. An older metric still in use; it captures the "apple versus pear" distribution pattern.

Central fat is the fat that acts on the liver, pancreas and blood vessels, so adding waist to BMI identifies high-risk people that BMI alone would reassure. Grade A 🟢

Measuring body composition: DXA, BIA and body-fat percentage

• DXA (dual-energy X-ray absorptiometry). The clinical reference standard for most patients: it separates fat mass, lean mass and bone, and can estimate visceral fat. Low radiation, quick, and best suited to tracking fat and muscle over time when a treatment could cost lean mass. → Exercise, Muscle & Body Composition
• BIA (bioelectrical impedance analysis). The technology in most smart scales and many clinic devices, which passes a small current through the body and estimates fat from resistance. Cheap and convenient, but sensitive to hydration, recent meals and exercise, so single readings are noisy and it suits trends on one device under consistent conditions rather than a precise one-time number.
• Other methods. Air-displacement plethysmography (Bod Pod), underwater weighing and MRI are accurate but largely research tools; skinfold calipers are cheap but operator-dependent.

Body-fat percentage puts a number on composition. Broad, non-diagnostic reference ranges of roughly 10–20% for men and 18–28% for women are often cited as healthy, rising with age, with obesity-range body fat commonly cited above ~25% in men and ~32% in women. These are approximate, and cutoffs vary by lab, method, age and ethnicity. Grade B 🟡

Obesity is not one phenotype

• Visceral (central, "apple") obesity. Fat concentrated around the organs; the most metabolically dangerous pattern, tightly linked to insulin resistance, fatty liver and cardiovascular disease even at a modest BMI.
• Subcutaneous ("pear") obesity. Fat under the skin, particularly hips and thighs; less metabolically harmful, and some depots may be relatively protective.
• Normal-weight obesity ("skinny fat"). Normal BMI with a high body-fat percentage and elevated metabolic risk, invisible to BMI alone.
• Sarcopenic obesity. High fat with low muscle, common with ageing; predicts poor function, falls and frailty, and is easy to miss at a normal BMI. Grade B 🟡
• Muscular "false-positive" obesity. High BMI from muscle rather than fat — the athlete misclassified by BMI.
• Metabolically healthy obesity (MHO). Obesity with currently normal blood pressure, glucose and lipids and no fatty liver. It is real, but often a transient stage that progresses, and it does not erase mechanical, oncologic and other risks, so it reads as lower-risk now rather than no risk. → What Is Obesity?

Ethnicity-specific cutoffs

Risk does not begin at the same BMI in every population. In South Asian, East Asian and some other populations, cardiometabolic risk — diabetes, fatty liver, cardiovascular disease — rises at lower BMI. The WHO and many national bodies therefore apply lower thresholds in these groups, with action points around BMI ~23 for overweight and ~27.5 for obesity in several Asian populations, against 25 and 30 in the standard tables, and correspondingly lower waist cutoffs.

A borderline BMI in a South Asian patient may therefore carry the risk of a considerably higher BMI in the reference population. One universal cutoff systematically under-detects risk in some groups and can over-label it in others. Grade A 🟢 → How Obesity Should Be Evaluated

Obesity staging: grading the disease, not the number

Modern obesity assessment has shifted from the size of the number to how much the adiposity is harming the person in front of the clinician, and staging systems formalise that. The Edmonton Obesity Staging System (EOSS) grades obesity 0–4 by the actual medical, functional and psychological burden, independent of BMI.

• Stage 0 — no apparent risk factors, no functional or psychological impairment.
• Stage 1 — subclinical risk factors such as borderline blood pressure, mild symptoms or impairment.
• Stage 2 — established comorbidity (diabetes, hypertension, fatty liver, sleep apnea) or moderate limitation.
• Stage 3 — significant end-organ damage.
• Stage 4 — severe, potentially end-stage disability from obesity-related disease.

Someone with BMI 33 and EOSS 0–1 is in a different clinical situation from someone with BMI 33 alongside diabetes, fatty liver and sleep apnea at EOSS 2–3, and EOSS predicts mortality better than BMI. That is why two people with the same BMI can reasonably receive very different treatment. Grade A 🟢 → Obesity as a Chronic Disease

Which measurements are worth taking in a given case — and which would only generate a number without changing the plan — is what an individual assessment at the practice decides.

Questions patients ask

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: WHO BMI classification and Asian-population BMI cutoffs; AACE/OMA guidance pairing BMI with waist and complications-based staging; Edmonton Obesity Staging System (Sharma & Kushner); consensus statements on waist-to-height ratio; DXA/BIA body-composition methodology. Educational; not individualized advice.